SCHEMBL1064437

SCHEMBL1064437

CC12C[C]3CC(C)(C1)CC(C)(C3)C2

nearest known ligand 0.31

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL988590 0.83
SCHEMBL4035431 0.77
SCHEMBL4033297 0.77
SCHEMBL989039 0.76
SCHEMBL4040761 0.71
SCHEMBL4035176 0.71
SCHEMBL6228377 0.69 PKM (0.37)
SCHEMBL8941008 0.69 PKM (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11405480 0.69 PKM (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL327129 0.68 GRIN1 (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4222180-B1 BIS(HETEROCYCLIC-OLATE) LEWIS BASE CATALYSTS AND METHODS THEREOF EXXONMOBIL CHEMICAL PATENTS INC (US) 2024-04-10 EP claimed
EP-4222180-A1 BIS(HETEROCYCLIC-OLATE) LEWIS BASE CATALYSTS AND METHODS THEREOF ExxonMobil Chemical Patents Inc. (US) 2023-08-09 EP claimed
CN-116323694-A Bis (heterocyclic-alkoxide) lewis base catalysts and methods thereof 埃克森美孚化学专利公司 2023-06-23 CN claimed
US-11766669-B2 Hexahydrocyclopenta[e]-as-indacen-1-yl and octahydrobenzo[e]-as-indacen-1-yl based catalyst complexes and process for use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-09-26 US disclosed
EP-4222180-A1 BIS(HETEROCYCLIC-OLATE) LEWIS BASE CATALYSTS AND METHODS THEREOF ExxonMobil Chemical Patents Inc. (US) 2023-08-09 EP disclosed
US-20210402384-A1 Hexahydrocyclopenta[e]-as-indacen-1-yl and Octahydrobenzo[e]-as-indacen-1-yl based Catalyst Complexes and Process for Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2021-12-30 US disclosed
CN-106715487-B Process for producing olefin (co) polymer containing constituent unit derived from 1-butene 三井化学株式会社 2021-02-26 CN disclosed
EP-3192817-B1 METHOD FOR PRODUCING OLEFIN (CO)POLYMER CONTAINING CONSTITUENT UNIT DERIVED FROM 1-BUTENE MITSUI CHEMICALS INC (JP) 2020-12-23 EP disclosed
US-10077254-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-09-18 US disclosed
EP-2975069-B1 METHOD FOR PRODUCING OLEFIN POLYMER AND CATALYST FOR OLEFIN POLYMERIZATION MITSUI CHEMICALS INC (JP) 2018-09-05 EP disclosed
US-9944728-B2 Production method of olefin (co)polymer containing constituent unit derived from 1-butene MITSUI CHEMICALS, INC. (JP) 2018-04-17 US disclosed
CN-1963667-B Chemically amplified positive resist composition SUMITOMO CHEMICAL CO 2010-09-29 CN disclosed
CN-100565340-C Chemically Amplified Photoresist Composition SUMITOMO CHEMICAL CO (JP) 2009-12-02 CN disclosed
US-7622399-B2 Method of forming low-k dielectrics using a rapid curing process SILECS OY (FI) 2009-11-24 US disclosed
US-7220532-B2 Chemical amplification type resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-22 US disclosed
CN-1963667-A Chemically amplified positive resist composition SUMITOMO CHEMICAL CO (JP) 2007-05-16 CN disclosed
US-20050064726-A1 Method of forming low-k dielectrics SILECS OY (FI) 2005-03-24 US disclosed
CN-1488996-A Chemically Amplified Photoresist Composition ס�ѻ�ѧ��ҵ��ʽ���� 2004-04-14 CN disclosed
US-20040053171-A1 Chemical amplification type resist composition SUMITOMO CHEMICAL COMPANY, LIMITED 2004-03-18 US disclosed
EP-0097127-A2 Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1983-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10077254-B2 Tetrazolinone compound and use thereof MT-CO1, UQCRB, MT-CO2 GRIN2D 2969/4885GRIN3B 2403/4885GRIN1 1092/4885
US-11766669-B2 Hexahydrocyclopenta[e]-as-indacen-1-yl and octahydrobenzo[e]-as-indacen-1-yl based catalyst complexes and process for use thereof MLX, ZYX, TXN GRIN2D 594/4885GRIN3B 1220/4885GRIN1 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.